DHR

Danaher Corporation

Fundamental data last updated:June 7, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Diagnostics & Research

Exchange

NYSE

County of HQ

US

Next Earnings Date

07/28/2026

Business Summary

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

 


VALUATION

P/E

35.37

Market Cap ($M USD)

$130.44B

Forward P/E

16.02

PEG

0.13

PRICE TO SALES

5.26

PRICE TO BOOK

2.46

EV / EBITDA

21.41

5-Year Average P/E

Free Cash Flow Yield

4.06%

DCF Value

$216.01

Graham Number

$93.65

Price to FCF

24.65

EV to FCF

27.07

Earnings Yield

2.83%

FCF Yield

4.06%

DIVIDEND

Yield

0.74%

Annual Payout

$1.36

Payout Ratio

24.67%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$5.21

Next Year EPS Growth Estimate

$11.50

Next Year Revenue Growth Estimate

$3.17T

Return on Equity (ROE)

7.06%

FREE CASH FLOW

Operating Margin

20.95%

Debt-to-Equity

0.35

Piotroski F-Score

6

Altman Z-Score

3.96

Return on Invested Capital (ROIC)

6.82%

Current Ratio

1.87

Quick Ratio

1.52

Net Debt to EBITDA

1.91

Interest Coverage

20.28

Gross Profit margin

60.68%

FCF PER SHARE

$7.47

REVENUE PER SHARE

$35.00

Gainseekers Quantitative Analysis

Summary

Danaher Corporation’s valuation presents a compelling narrative for value investors. With a Forward P/E of 14.42, the market seems to underestimate its growth potential, especially when juxtaposed with a DCF value significantly higher than recent pricing. The Graham Number suggests a conservative intrinsic value, indicating potential undervaluation. Meanwhile, an Altman Z-score of 3.75 underscores financial stability, and an earnings yield of 3.13% suggests room for growth. This stock appears to be a hidden gem, mispriced relative to its intrinsic value.

AI Exposure / Tech Reliance

Operating in the Medical - Diagnostics & Research industry, Danaher is well-positioned to leverage AI advancements. The healthcare sector's increasing reliance on data analytics and diagnostics innovation aligns perfectly with Danaher's core competencies. This strategic alignment could enhance its competitive edge and operational efficiency.

The Bull Case

For GARP investors, Danaher offers a robust case. With a ROIC of 6.82% and a Piotroski F-Score of 6, the company demonstrates efficient capital allocation and solid financial health. Its FCF Yield, though modest, is supported by a strong operating margin of 20.95%, indicating effective cost management and pricing power. These metrics suggest a company capable of generating sustainable returns and capitalizing on growth opportunities.

The Bear Case

Despite its strengths, Danaher faces challenges. The Price/Sales ratio of 4.76 and Price/Book of 2.23 indicate a premium valuation, potentially limiting upside. Additionally, the stock's proximity to its 52-week high raises concerns about technical overextension. Investors should be cautious of these valuation pressures, which could hinder future appreciation.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$238.30

Institutional Ownership %

1-Year Beta

0.84

Insider Buying % (6 Mo)

Distance to 52-Week High

31.74%

Distance to 52-Week Low

12.68%

EARNINGS SURPRISE %

6.19%

50-DAY SMA

$181.08

200-DAY SMA

$205.61

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.